Prof. Christer Wingren is head of the Affinity Proteomics research unit at CREATE Health, Centre of IDEA and the Dept. of Immunotechnology, Lund University, Sweden. He directs a research group working on the development and application of recombinant antibody microarrays for high-throughput disease proteomics, with a particular focus on oncoproteomics and autoimmunity. For these indications, current diagnostic, prognostic, classification and therapeutic approaches are associated with major problems. To resolve these unmet key clinical needs, we perform translational research, going from the “bed-to-bench and back again”. The overall objective is to decode these indications, using an innovative approach. It is based on the hypothesis that blood harbors massive amounts of actionable information of clinical utility. The cancer projects are focused towards pancreatic cancer, breast cancer, and prostate cancer. Using a state-of-the-art antibody array profiling platform, we generate disease-specific protein maps from a single drop of blood. These unique maps are used to decode the target disease at a molecular level. This will generate a deep understanding of the underlying disease biology. The information will also be translated into clinically useful tools for early diagnosis, prognosis, classification, and evidence-based therapy selection. Thus, providing the clinicians with novel actionable information, paving the way for personalized medicine.